GlassScriptPhysician profile
Farshid Yazdi
NPI 1679707350
$13,715.03
in general payments reported to CMS, 2019-2025
26 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,782 · 2020: $595 · 2021: $832 · 2022: $5,104 · 2023: $631 · 2024: $3,753 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Food and Beverage: $2,386 · Travel and Lodging: $417 · Education: $98.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Food and Beverage | $2,385.99 |
| Travel and Lodging | $416.96 |
| Education | $98.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $4,454.83 | 2019-2025 | Crit-Line, Optiflux |
| Calliditas Therapeutics US INC. | $3,164.87 | 2022-2025 | Tarpeyo |
| Amgen INC. | $759.58 | 2019-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $682.06 | 2019-2023 | Korsuva, Veltassa |
| Astrazeneca Pharmaceuticals LP | $657.00 | 2019-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $535.04 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $523.12 | 2019-2025 | Ultomiris, Soliris |
| Aurinia Pharma U.S., INC. | $466.88 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $353.87 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $290.65 | 2020-2025 | Acthar |
| Vantive US Healthcare LLC | $286.09 | 2025 | Renal - Pd |
| Baxter Healthcare | $248.37 | 2019-2023 | Renal - Pd |
| Mallinckrodt Enterprises LLC | $248.25 | 2019 | |
| Akebia Therapeutics INC | $246.73 | 2019-2025 | Vafseo |
| Novartis Pharmaceuticals Corporation | $191.37 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $134.44 | 2022 | |
| Horizon Therapeutics Plc | $106.62 | 2023 | Krystexxa |
| Travere Therapeutics, INC. | $105.41 | 2022-2025 | |
| Rockwell Medical, INC. | $60.60 | 2019 | |
| Glaxosmithkline, LLC. | $44.60 | 2022-2024 | Benlysta |
| Abbvie INC. | $39.51 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $38.22 | 2022-2025 | Jynarque |
| Ultragenyx Pharmaceutical INC. | $22.41 | 2024 | Crysvita |
| Octapharma USA, INC. | $20.34 | 2024 | Octagam Immune Globulin (Human) |
| Terumo Medical Corporation | $19.35 | 2024 | Angio-Seal |
| Bard Peripheral Vascular, INC. | $14.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farshid Yazdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.